Annovis Bio (NYSE:ANVS) reported its full-year 2025 financial results and clinical milestones on March 16, 2026, highlighting a period of aggressive execution for its neurodegenerative disease pipeline.
The Malvern, Pennsylvania-based company is currently focused on its pivotal Phase 3 trial of buntanetap in patients with early-stage Alzheimer’s Disease (AD).
Management confirmed that the study has reached 65% enrollment across 83 clinical sites in the United States, keeping the program on track for a critical symptomatic efficacy readout in early 2027.
Beyond the Alzheimer's program, Annovis has launched an Open-Label Extension (OLE) study for its Parkinson’s Disease (PD) program.
This follow-up study allows patients who completed initial trials to continue receiving buntanetap, providing essential long-term safety data required for a future New Drug Application (NDA).
In a significant win for the company’s long-term valuation, Annovis also secured extended patent protection for a new crystal form of buntanetap, stretching its intellectual property moat to 2047.